Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
January 7th, 2019
8.3K views
This manuscript describes a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) CRISPR-Cas9-based method for simple and expeditious investigation of the role of multiple candidate genes in Acute Myeloid Leukemia (AML) cell proliferation in parallel. This technique is scalable and can be applied in other cancer cell lines as well.
Overview
This manuscript describes a CRISPR-Cas9-based method for investigating the role of multiple candidate genes in Acute Myeloid Leukemia (AML) cell proliferation. The technique is rapid, scalable, and applicable to other cancer cell lines.
Key Study Components
Area of Science
- Neuroscience
- Genetics
- Cancer Research
Background
- Acute Myeloid Leukemia (AML) is a type of cancer affecting the blood and bone marrow.
- Understanding gene roles in AML can lead to better treatment strategies.
- CRISPR-Cas9 technology allows for precise genetic modifications.
- Flow cytometry can be used to analyze cell growth and proliferation.
Purpose of Study
- To develop a method for investigating multiple genes in AML simultaneously.
- To enhance the speed and scalability of genetic studies in cancer research.
- To provide a framework that can be applied to other cancer cell lines.
Methods Used
- CRISPR-Cas9 system for gene editing.
- Flow cytometry-based competitive growth assay.
- Designing single guide RNAs using web-based software.
- Parallel investigation of multiple candidate genes.
Main Results
- The method allows for rapid assessment of gene function in AML.
- Demonstrated scalability for use in various cancer cell lines.
- Provided insights into the proliferation mechanisms of AML cells.
- Facilitated the identification of potential therapeutic targets.
Conclusions
- The CRISPR-Cas9 method is effective for studying gene roles in AML.
- This approach can accelerate cancer research and therapeutic development.
- Future applications may extend to other types of cancer.
Frequently Asked Questions
What is the CRISPR-Cas9 system?
The CRISPR-Cas9 system is a powerful tool for editing genes, allowing researchers to modify DNA sequences and regulate gene activity.
How does flow cytometry work?
Flow cytometry is a technique used to analyze the physical and chemical characteristics of cells or particles in a fluid as they pass through a laser.
What are candidate genes?
Candidate genes are genes that are suspected to be involved in a particular disease or trait based on previous research or biological knowledge.
Why is scalability important in cancer research?
Scalability allows researchers to apply methods to larger sample sizes or different cell lines, increasing the robustness and applicability of findings.
What are the implications of this research for AML treatment?
This research may lead to the identification of new therapeutic targets, improving treatment strategies for patients with Acute Myeloid Leukemia.
Executive Industry Relevance
This CRISPR-Cas9-based competition assay enables rapid, parallel interrogation of gene dependencies in AML cell lines, supporting target validation and mechanistic de-risking in early discovery. By linking genetic perturbation to quantitative proliferation readouts via flow cytometry, the method provides predictive confidence for prioritizing therapeutic targets and streamlines hit-to-lead decision-making in oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables hypothesis-driven interrogation of candidate genes in AML proliferation and survival pathways.
- Operational Value: Supports scalable testing of 16–24 genes in parallel using 4–6 sgRNAs per gene.
- Strategic Value: Facilitates target de-risking by quantifying competitive fitness effects of gene loss.
Screening & Assay Development
- Scientific Value: Generates quantitative, reproducible BFP-positive cell percentages as a proxy for gene dependency.
- Operational Value: Uses standardized flow cytometry gating to ensure accurate live-cell quantification across time points.
- Strategic Value: Enables assay standardization and cross-run comparability for hit confirmation.
Translational & Preclinical Research
- Scientific Value: Confirms gene essentiality in murine MLL-AF9 and human MOM13 Cas9 AML models, supporting translational continuity.
- Operational Value: Applicable to any cancer cell line, enabling platform reuse across indications.
- Strategic Value: Informs preclinical target selection by distinguishing essential genes (e.g., Dot1l, RPA3) from non-essential controls (e.g., Rhodopsin, AAVS1).
Pipeline & Workflow Integration
The method fits within the discovery continuum from target identification to lead optimization, providing functional validation that bridges genomic hits to phenotypic consequences in AML models.
- Discovery Biology: Supports mechanistic interrogation of gene function in leukemia cell fitness and pathway dependency.
- Screening: Delivers assay-ready, genetically perturbed cell populations with measurable growth phenotypes.
- Analytics: Outputs time-resolved BFP-positive cell percentages enabling comparative fitness analysis.
- Translational Research: Demonstrates conservation of gene dependency across human and murine AML models, supporting cross-species validity.
- Enterprise Reuse: Compatible with 96-well formats and lentiviral delivery, enabling scalable deployment across projects.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by linking genotype to competitive proliferation phenotypes.
- Operational Value: Standardized workflow from sgRNA design to flow cytometry readout ensures reproducibility.
- Strategic Value: Improves go/no-go decisions by quantifying gene essentiality early in target validation.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on dependency strength and phenotypic penetrance.
Implementation Considerations
- Requires expertise in molecular cloning, lentiviral production, and flow cytometry.
- Dependent on access to Cas9-expressing AML cell lines and BFP reporter systems.
- Necessitates standardized annealing, ligation, and transformation protocols for sgRNA library generation.
- Requires optimization of transduction efficiency and selection markers for each cell line.
- Limited by the need for sequence validation of cloned sgRNAs prior to viral production.
Biopharma FAQs
Why does flow cytometry-based competition assay matter for target validation?
The assay quantifies the relative proliferation of gene-perturbed cells versus unperturbed controls over time, providing a functional readout of gene dependency in AML models. This enables objective assessment of whether a gene is required for cell fitness or survival.
How does sgRNA design and cloning support parallel gene interrogation?
The method uses web-based tools to design 4–6 sgRNAs per gene, which are cloned into a lentiviral vector in 96-well format, enabling simultaneous targeting of multiple genes. This approach increases on-target efficiency and reduces false negatives due to sgRNA variability.
What does the percentage of BFP-positive cells measure in this assay?
The percentage of BFP-positive cells reflects the proportion of cells successfully transduced with a given sgRNA, allowing tracking of their relative abundance compared to BFP-negative (untransduced) counterparts. A decline in BFP-positive cells indicates a proliferative or survival disadvantage upon gene perturbation.
Why are replication and time-point sampling critical in the competition assay?
Re-plating cells every 2–3 days and repeated flow cytometry analysis prevent overgrowth and ensure accurate measurement of relative fitness changes across time. This longitudinal design captures dynamic effects of gene loss on proliferation.
What statistical analysis is needed to interpret competitive proliferation data?
Analysis requires comparing the percentage of BFP-positive cells across time points for each sgRNA condition relative to controls, using tools like table editors and batch reporting to generate Excel-compatible outputs. Trends in depletion or enrichment inform gene essentiality calls.
